Tudor Eliade Ciuleanu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7640160/publications.pdf

Version: 2024-02-01

38 papers	14,528 citations	377584 21 h-index	371746 37 g-index
39 all docs	39 docs citations	39 times ranked	11118 citing authors

#	Article	IF	Citations
1	Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. European Urology, 2022, 82, 283-292.	0.9	14
2	Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients. International Journal of Environmental Research and Public Health, 2022, 19, 4314.	1.2	5
3	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. OncoTargets and Therapy, 2021, Volume 14, 5275-5291.	1.0	5
4	Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. British Journal of Cancer, 2020, 122, 1461-1466.	2.9	24
5	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	1.3	112
6	Durvalumab plus platinumâ€“etoposide versus platinumâ€“etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2019, 394, 1929-1939.	6.3	1,274
7	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open, 2018, 3, e000347.	2.0	15
8	Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 130-138.e2.	1.1	19
9	Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. International Journal of Cancer, 2018, 142, 66-80.	2.3	13
10	A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer, 2017, 17, 137.	1.1	47
11	Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. European Journal of Cancer, 2017, 78, 61-69.	1.3	25
12	Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer, 2017, 104, 45-51.	0.9	9
13	Exposureâ€“response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemotherapy and Pharmacology, 2017, 80, 599-608.	1.1	18
14	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Nonâ€“Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. Journal of Thoracic Oncology, 2016, 11, 545-555.	0.5	87
15	Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment. Journal of Medical Ultrasonics (2001), 2015, 42, 271-276.	0.6	10
16	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Translational Lung Cancer Research, 2015, 4, 465-74.	1.3	21
17	Development and Evaluation of a Software-based Clinical Pharmacography System. Studies in Informatics and Control, 2015, 24, .	0.6	0
18	Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. Journal of Thoracic Oncology, 2014, 9, 1345-1353.	0.5	416

#	Article	IF	Citations
19	Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. Expert Opinion on Pharmacotherapy, 2012, 13, 159-174.	0.9	14
20	Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Nonâ€“Small-Cell Lung Cancer: A Lead-In Study. Journal of Thoracic Oncology, 2012, 7, 1406-1416.	0.5	22
21	Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncology, The, 2012, 13, 300-308.	5.1	360
22	Second-line erlotinib for non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2012, 13, e142.	5.1	0
23	Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Nonâ€“Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. Journal of Clinical Oncology, 2012, 30, 3640-3647.	0.8	166
24	A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer, 2012, 78, 63-69.	0.9	22
25	Profiling immunohistochemical expression of NOTCH1â€“3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. Clinical and Experimental Metastasis, 2012, 29, 603-614.	1.7	15
26	A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 have failed first-line gemcitabine therapy. Investigational New Drugs, 2012, 30, 1216-1223.	1.2	196
27	The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. International Journal of Cancer, 2010, 127, 2209-2221.	2.3	464
28	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncology, The, 2010, 11, 521-529.	5.1	1,158
29	Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 4787-4792.	0.8	176
30	Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemotherapy and Pharmacology, 2009, 64, 233-241.	1.1	18
31	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01,) Tj ETQq1 1 0.784314 rgBT /Ov 10, 467-474.	5.1	318
32	Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, The, 2009, 374, 1432-1440.	6.3	1,062
33	XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy. Journal of Thoracic Oncology, 2009, 4, 736-740.	0.5	81
34	A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung Cancer, 2007, 57, 168-174.	0.9	7
35	Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5034-5042.	0.8	701
36	Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer, 2006, 52, 155-163.	0.9	304

#	Article	IF	Citations
37	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa) Tj ETQq1 1 0.784314 rgBT /Overlo	6.3	2,167
38	Erlotinib in Previously Treated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2005, 353, 123-132.	13.9	5,267